Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes

Ben Gary Harvey, Robin L. McKinney, Todd Rosengart, Martin L. Lesser, Ronald Crystal

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1- E3- Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) AdGVCFTR.10, a vector carrying the normal human CFTR cDNA (3 × 107 to 2 × 1010 particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) AdGVVEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 × 108 to 4 × 1010 pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 × 108 to 4 × 109.5 pu) of individuals with peripheral vascular disease (PVD); and 3) AdGVCD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 × 107 to 7 × 109 pu) and airways (7 × 108 to 7 × 1010 pu) of normal individuals and to liver metastasis (4 × 108 to 4 × 109 pu) of individuals with colon carcinoma. IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively. IL-6 responses were higher (up to 1100 pg/ml) following myocardial administration. Control individuals who had chest surgery and bronchoscopy, but no vector administration, had comparable IL-6 increases. Thus, both administration of Ad vectors of humans up to 1010 pu and the procedures used to administer the vectors elicit systemic IL-6 responses. There was no correlation among peak IL-6 and peak anti-Ad antibodies. These observations indicate that the innate host responses following administration of Ad vectors to humans may result from the procedures used to administer the vector, and from the vector per se.

Original languageEnglish
Pages (from-to)287-297
Number of pages11
JournalMolecular Therapy
Volume6
Issue number2
DOIs
Publication statusPublished - 1 Jul 2002
Externally publishedYes

Fingerprint

Adenoviridae
Interleukin-6
Genes
Peripheral Vascular Diseases
Cystic Fibrosis
Complementary DNA
Cytosine Deaminase
Neoplasm Metastasis
Human Adenoviruses
Muscles
Skin
Liver
Bronchoscopy
Neutralizing Antibodies
Innate Immunity
Colonic Neoplasms
Coronary Artery Disease
Anti-Idiotypic Antibodies
Lower Extremity
Myocardium

Keywords

  • Ad vectors
  • Anti-Ad-neutralizing metabolism
  • Gene therapy
  • Human
  • IL-6
  • Innate responses

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. / Harvey, Ben Gary; McKinney, Robin L.; Rosengart, Todd; Lesser, Martin L.; Crystal, Ronald.

In: Molecular Therapy, Vol. 6, No. 2, 01.07.2002, p. 287-297.

Research output: Contribution to journalReview article

Harvey, Ben Gary ; McKinney, Robin L. ; Rosengart, Todd ; Lesser, Martin L. ; Crystal, Ronald. / Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. In: Molecular Therapy. 2002 ; Vol. 6, No. 2. pp. 287-297.
@article{a92143663f294cc4b8d2ed059a0bc34b,
title = "Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes",
abstract = "Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1- E3- Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) AdGVCFTR.10, a vector carrying the normal human CFTR cDNA (3 × 107 to 2 × 1010 particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) AdGVVEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 × 108 to 4 × 1010 pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 × 108 to 4 × 109.5 pu) of individuals with peripheral vascular disease (PVD); and 3) AdGVCD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 × 107 to 7 × 109 pu) and airways (7 × 108 to 7 × 1010 pu) of normal individuals and to liver metastasis (4 × 108 to 4 × 109 pu) of individuals with colon carcinoma. IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively. IL-6 responses were higher (up to 1100 pg/ml) following myocardial administration. Control individuals who had chest surgery and bronchoscopy, but no vector administration, had comparable IL-6 increases. Thus, both administration of Ad vectors of humans up to 1010 pu and the procedures used to administer the vectors elicit systemic IL-6 responses. There was no correlation among peak IL-6 and peak anti-Ad antibodies. These observations indicate that the innate host responses following administration of Ad vectors to humans may result from the procedures used to administer the vector, and from the vector per se.",
keywords = "Ad vectors, Anti-Ad-neutralizing metabolism, Gene therapy, Human, IL-6, Innate responses",
author = "Harvey, {Ben Gary} and McKinney, {Robin L.} and Todd Rosengart and Lesser, {Martin L.} and Ronald Crystal",
year = "2002",
month = "7",
day = "1",
doi = "10.1006/mthe.2002.0658",
language = "English",
volume = "6",
pages = "287--297",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes

AU - Harvey, Ben Gary

AU - McKinney, Robin L.

AU - Rosengart, Todd

AU - Lesser, Martin L.

AU - Crystal, Ronald

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1- E3- Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) AdGVCFTR.10, a vector carrying the normal human CFTR cDNA (3 × 107 to 2 × 1010 particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) AdGVVEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 × 108 to 4 × 1010 pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 × 108 to 4 × 109.5 pu) of individuals with peripheral vascular disease (PVD); and 3) AdGVCD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 × 107 to 7 × 109 pu) and airways (7 × 108 to 7 × 1010 pu) of normal individuals and to liver metastasis (4 × 108 to 4 × 109 pu) of individuals with colon carcinoma. IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively. IL-6 responses were higher (up to 1100 pg/ml) following myocardial administration. Control individuals who had chest surgery and bronchoscopy, but no vector administration, had comparable IL-6 increases. Thus, both administration of Ad vectors of humans up to 1010 pu and the procedures used to administer the vectors elicit systemic IL-6 responses. There was no correlation among peak IL-6 and peak anti-Ad antibodies. These observations indicate that the innate host responses following administration of Ad vectors to humans may result from the procedures used to administer the vector, and from the vector per se.

AB - Administration of adenovirus (Ad) vectors to animals induces innate immune responses, typified by elevated interleukin-6 (IL-6). To assess innate responses to Ad vectors in humans, we evaluated serum IL-6 following administration of E1- E3- Ad vectors to different human hosts and the relationship among peak IL-6 and peak anti-Ad neutralizing antibodies. We administered: 1) AdGVCFTR.10, a vector carrying the normal human CFTR cDNA (3 × 107 to 2 × 1010 particle units (pu)) to airways of individuals with cystic fibrosis (CF); 2) AdGVVEGF121.10, a vector carrying the normal human vascular endothelial growth factor (VEGF)121 cDNA, to the myocardium (4 × 108 to 4 × 1010 pu) of individuals with coronary artery disease (CAD) and to lower extremity muscles (4 × 108 to 4 × 109.5 pu) of individuals with peripheral vascular disease (PVD); and 3) AdGVCD.10, a vector carrying the Escherichia coli cytosine deaminase gene to skin (7 × 107 to 7 × 109 pu) and airways (7 × 108 to 7 × 1010 pu) of normal individuals and to liver metastasis (4 × 108 to 4 × 109 pu) of individuals with colon carcinoma. IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively. IL-6 responses were higher (up to 1100 pg/ml) following myocardial administration. Control individuals who had chest surgery and bronchoscopy, but no vector administration, had comparable IL-6 increases. Thus, both administration of Ad vectors of humans up to 1010 pu and the procedures used to administer the vectors elicit systemic IL-6 responses. There was no correlation among peak IL-6 and peak anti-Ad antibodies. These observations indicate that the innate host responses following administration of Ad vectors to humans may result from the procedures used to administer the vector, and from the vector per se.

KW - Ad vectors

KW - Anti-Ad-neutralizing metabolism

KW - Gene therapy

KW - Human

KW - IL-6

KW - Innate responses

UR - http://www.scopus.com/inward/record.url?scp=0036664450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036664450&partnerID=8YFLogxK

U2 - 10.1006/mthe.2002.0658

DO - 10.1006/mthe.2002.0658

M3 - Review article

C2 - 12349828

AN - SCOPUS:0036664450

VL - 6

SP - 287

EP - 297

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -